Severe Asthma Market to Grow at a Substantial Growth Rate During the Forecast Period (2032) – Estimates DelveInsight | AstraZeneca (Tezspire/tezepelumab), GSK3511294 (Depemokimab), Novartis, Sanofi

Severe Asthma Market to Grow at a Substantial Growth Rate During the Forecast Period (2032) -  Estimates DelveInsight | AstraZeneca (Tezspire/tezepelumab), GSK3511294 (Depemokimab), Novartis, Sanofi
Delveinsight Business Research LLP
As per DelveInsight, the Severe Asthma Market size was found to be USD 6,076 Million in 2021, which is expected to grow by 2032. The market is expected to grow owing to the expected launch of potential therapies, an increase in the diagnosed prevalent population of Severe Asthma, and rising demand for personalized therapies in the 7MM.

DelveInsight’s “Severe Asthma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Severe Asthma Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Severe Asthma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Severe Asthma Market

Severe Asthma: An Overview

Asthma is the most common chronic respiratory disease all over the globe. It affects the airways in the lungs, which become inflamed and narrowed due to various triggers, making it harder for air to flow out. A complex activity between airway inflammation and airway remodeling that results in airway hyper-responsiveness (AHR), which further leads to variable and excessive airway contraction.

There is no single treatment for severe asthma, and the current treatment focuses on controlling the symptoms, managing airway inflammation, and preventing lung damage. Besides inhalers, severe asthmatics are prescribed inhaled corticosteroids and additional long-term controller medicines like bronchodilators, leukotriene receptor antagonists, LAMAs, LABAs, and slow-release theophylline. 

Severe Asthma Market Key Facts

  • The total diagnosed prevalent (adult + pediatric) cases of asthma in the 7MM were observed to be 54,215,617 cases in 2021. These cases are expected to increase by 2032.

  • Among 7MM, the United States had the highest number of diagnosed adult asthma cases, with 20,868,845 cases in 2021. The cases are expected to increase by 2032.

  • Among the European countries, the UK accounted for the highest number of asthma diagnosed prevalent (adult + pediatric) cases (5,884,988), followed by France in 2021. In contrast, Spain accounted for the lowest number of cases of the total diagnosed prevalent population in the EU-5 for 2021.

  • The Severe Asthma pipeline is active with several new generation products in the early and late stages of development that have the potential for a positive shift in the treatment market. The key assets include GSK3511294 (GlaxoSmithKline), PT010 (AstraZeneca), PT027 (AstraZeneca and Bond Avillion), CSJ117 (Novartis), MRx-4DP0004 (4D pharma), RG6173 (Roche), BSI-045B (Biosion), etc. that will have a significant impact on market size in the future.

Severe Asthma Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Severe Asthma market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Severe Asthma market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Severe Asthma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

Severe Asthma Epidemiology Segmentation

  • Severity-specific Diagnosed Prevalent Cases of Asthma 

  • Type-specific Diagnosed Prevalent Cases of Severe Asthma 

  • Total Diagnosed Prevalent (adult + pediatric) Cases Asthma

Severe Asthma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Severe Asthma market or expected to get launched during the study period. The analysis covers Severe Asthma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Severe Asthma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Recent Developments in the Severe Asthma Therapeutics Market 

On 21 September 2022, AstraZeneca AZN announced that the European Commission had granted approval to its monoclonal antibody, Tezspire (tezepelumab), as an add-on maintenance treatment in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product.

Learn How Severe Asthma Market Will Evolve by 2032 @

Severe Asthma Therapeutics Analysis

With already six approved biologics for treatment, the severe asthma pipeline is robust and dynamic, with many products being developed across different stages for different asthma phenotypes.

The expected launch of potential therapies may increase market size in the coming years, assisted by an increase in the diagnosed prevalent population of Severe Asthma. Upcoming therapies such as GSK3511294 (Depemokimab) and PT027 have the potential to create a significant positive shift in the Severe Asthma market size.

Some of the key companies in the Severe Asthma Market Include:

  • AstraZeneca

  • GlaxoSmithKline (GSK)

  • Novartis

  • Sanofi

  • Avillion

  • 4D Pharma plc

  • AB Pharma

  • Morphosys

  • Roche

  • Avalo Therapeutics

  • Pieris Pharma

  • Teva Pharmaceutical

  • Biosion

  • Regeneron Pharmaceutical

  • Suzhou Connect Biopharmaceuticals

Several other companies are also investigating drugs for the treatment of Severe Asthma.

Severe Asthma Therapies covered in the report include:

  • GSK3511294 (depemokimab) (GSK)

  • PT027 (AstraZeneca)

  • PT010 (AstraZeneca)

  • MRx-4DP0004 (4D Pharma plc)

  • CSJ117 (Ecleralimab) (Novartis)

  • AVTX-002 (Avalo Therapeutics)

  • BSI-045B (Biosion)

And many more

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More –

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Severe Asthma Competitive Intelligence Analysis

4. Severe Asthma Market Overview at a Glance

5. Severe Asthma Disease Background and Overview

6. Severe Asthma Patient Journey

7. Severe Asthma Epidemiology and Patient Population (In US, EU5, and Japan)

8. Severe Asthma Treatment Algorithm, Current Treatment, and Medical Practices

9. Severe Asthma Unmet Needs

10. Key Endpoints of Severe Asthma Treatment

11. Severe Asthma Marketed Products

12. Severe Asthma Emerging Drugs and Latest Therapeutic Advances

13. Severe Asthma Seven Major Market Analysis

14. Attribute Analysis

15. Severe Asthma Market Outlook (In US, EU5, and Japan)

16. Severe Asthma Access and Reimbursement Overview

17. KOL Views on the Severe Asthma Market

18. Severe Asthma Market Drivers

19. Severe Asthma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Varicose Veins Market

“Varicose Veins Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Varicose Veins Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States